Pharmacological characterization of the human 5-HT(4(d)) receptor splice variant stably expressed in Chinese hamster ovary cells. 2000

J Mialet, and I Berque-Bestel, and S Sicsic, and M Langlois, and R Fischmeister, and F Lezoualc'h
Laboratoire de Cardiologie Cellulaire et Moléculaire, INSERM U-446, Université de Paris-Sud, Faculté de Pharmacie, F-92296 Ch atenay-Malabry, France.

The recently identified C-terminal splice variant of the human 5-HT(4) receptor, the h5-HT(4(d)) receptor, was stably expressed in a CHO cell line at 493+/-25 fmol mg(-1) protein. We analysed its pharmacological properties by measuring binding affinities and 5-HT(4) ligand-induced cyclic AMP production. The pharmacological binding profile determined in competition studies with the specific antagonist [(3)H]-GR113808 revealed a rank order of affinity of 5-HT(4) ligands for the h5-HT(4(d)) receptor that was consistent with those previously reported for other 5-HT(4) receptor isoforms. In adenylyl cyclase functional assays, the h5-HT(4(d)) receptor displayed equipotent coupling for all 5-HT(4) agonists tested (EC(50) in the range of 1 - 6 nM). EC(50) values were lower than those previously obtained with the 5-HT(4(e)) receptor stably expressed in CHO cells indicating that the 5-HT(4(d)) receptor was more efficiently coupled to its effector than the 5-HT(4(e)) receptor isoform. Moreover, in terms of agonist efficacy (E(max)), the benzamide derivative, renzapride displayed full agonist properties at the h5-HT(4(d)) receptor (same E(max) as 5-HT) whereas it was previously shown to be a partial agonist at the h5-HT(4(e)) receptor. A constitutive activity of the h5-HT(4(d)) receptor was observed in CHO cells in the absence of any 5-HT(4) ligand. Surprisingly, two 5-HT(4) ligands, SB204070 and RS39604 which are described as highly potent antagonists in various biological models, revealed partial agonist properties at the h5-HT(4(d)) receptor. We conclude that C-terminal tails of 5-HT(4) receptor isoforms may directly influence their functional properties.

UI MeSH Term Description Entries
D007211 Indoles Benzopyrroles with the nitrogen at the number one carbon adjacent to the benzyl portion, in contrast to ISOINDOLES which have the nitrogen away from the six-membered ring.
D011985 Receptors, Serotonin Cell-surface proteins that bind SEROTONIN and trigger intracellular changes which influence the behavior of cells. Several types of serotonin receptors have been recognized which differ in their pharmacology, molecular biology, and mode of action. 5-HT Receptor,5-HT Receptors,5-Hydroxytryptamine Receptor,5-Hydroxytryptamine Receptors,Receptors, Tryptamine,Serotonin Receptor,Serotonin Receptors,Tryptamine Receptor,Tryptamine Receptors,Receptors, 5-HT,Receptors, 5-Hydroxytryptamine,5 HT Receptor,5 HT Receptors,5 Hydroxytryptamine Receptor,5 Hydroxytryptamine Receptors,Receptor, 5-HT,Receptor, 5-Hydroxytryptamine,Receptor, Serotonin,Receptor, Tryptamine,Receptors, 5 HT,Receptors, 5 Hydroxytryptamine
D006224 Cricetinae A subfamily in the family MURIDAE, comprising the hamsters. Four of the more common genera are Cricetus, CRICETULUS; MESOCRICETUS; and PHODOPUS. Cricetus,Hamsters,Hamster
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000242 Cyclic AMP An adenine nucleotide containing one phosphate group which is esterified to both the 3'- and 5'-positions of the sugar moiety. It is a second messenger and a key intracellular regulator, functioning as a mediator of activity for a number of hormones, including epinephrine, glucagon, and ACTH. Adenosine Cyclic 3',5'-Monophosphate,Adenosine Cyclic 3,5 Monophosphate,Adenosine Cyclic Monophosphate,Adenosine Cyclic-3',5'-Monophosphate,Cyclic AMP, (R)-Isomer,Cyclic AMP, Disodium Salt,Cyclic AMP, Monoammonium Salt,Cyclic AMP, Monopotassium Salt,Cyclic AMP, Monosodium Salt,Cyclic AMP, Sodium Salt,3',5'-Monophosphate, Adenosine Cyclic,AMP, Cyclic,Adenosine Cyclic 3',5' Monophosphate,Cyclic 3',5'-Monophosphate, Adenosine,Cyclic Monophosphate, Adenosine,Cyclic-3',5'-Monophosphate, Adenosine,Monophosphate, Adenosine Cyclic
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D013449 Sulfonamides A group of compounds that contain the structure SO2NH2. Sulfonamide,Sulfonamide Mixture,Sulfonamide Mixtures,Mixture, Sulfonamide,Mixtures, Sulfonamide
D016466 CHO Cells CELL LINE derived from the ovary of the Chinese hamster, Cricetulus griseus (CRICETULUS). The species is a favorite for cytogenetic studies because of its small chromosome number. The cell line has provided model systems for the study of genetic alterations in cultured mammalian cells. CHO Cell,Cell, CHO,Cells, CHO
D044422 Receptors, Serotonin, 5-HT4 A subtype of G-protein-coupled SEROTONIN receptors that preferentially couple to GS STIMULATORY G-PROTEINS resulting in increased intracellular CYCLIC AMP. Several isoforms of the receptor exist due to ALTERNATIVE SPLICING of its mRNA. Receptors, Serotonin, 5-HT4L,Receptors, Serotonin, 5-HT4S,Serotonin 4 Receptor,5-HT4 Receptor,5-HT4L Receptor,5-HT4S Receptor,5-Hydroxytryptamine-4 Receptor,Receptor, Serotonin 4,Serotonin 4 Receptors,5 HT4 Receptor,5 HT4L Receptor,5 HT4S Receptor,5 Hydroxytryptamine 4 Receptor,Receptor, 5-HT4,Receptor, 5-HT4L,Receptor, 5-HT4S,Receptor, 5-Hydroxytryptamine-4,Receptors, Serotonin 4

Related Publications

J Mialet, and I Berque-Bestel, and S Sicsic, and M Langlois, and R Fischmeister, and F Lezoualc'h
July 1994, British journal of pharmacology,
J Mialet, and I Berque-Bestel, and S Sicsic, and M Langlois, and R Fischmeister, and F Lezoualc'h
December 1998, British journal of pharmacology,
J Mialet, and I Berque-Bestel, and S Sicsic, and M Langlois, and R Fischmeister, and F Lezoualc'h
July 1996, Molecular pharmacology,
J Mialet, and I Berque-Bestel, and S Sicsic, and M Langlois, and R Fischmeister, and F Lezoualc'h
March 1996, British journal of pharmacology,
J Mialet, and I Berque-Bestel, and S Sicsic, and M Langlois, and R Fischmeister, and F Lezoualc'h
March 2000, The Journal of biological chemistry,
J Mialet, and I Berque-Bestel, and S Sicsic, and M Langlois, and R Fischmeister, and F Lezoualc'h
January 1993, The Journal of biological chemistry,
J Mialet, and I Berque-Bestel, and S Sicsic, and M Langlois, and R Fischmeister, and F Lezoualc'h
July 1989, Journal of biochemistry,
J Mialet, and I Berque-Bestel, and S Sicsic, and M Langlois, and R Fischmeister, and F Lezoualc'h
February 1994, Biochemical Society transactions,
J Mialet, and I Berque-Bestel, and S Sicsic, and M Langlois, and R Fischmeister, and F Lezoualc'h
January 1993, Journal of receptor research,
J Mialet, and I Berque-Bestel, and S Sicsic, and M Langlois, and R Fischmeister, and F Lezoualc'h
October 1992, Glycobiology,
Copied contents to your clipboard!